摘要
目的观察骨松宝联合钙尔奇D治疗骨量减少和骨质疏松症患者以改善其骨密度的疗效。方法将80例骨量减少和骨质疏松症患者随机分为两组,分别口服骨松宝联合钙尔奇D治疗(观察组)和单用钙尔奇D治疗(对照组),服药6个月后观察骨密度值的变化。结果观察组与对照组BMD值和T值均有改善。观察组治疗前后腰椎BMD值分别为(0.60±0.12)和(0.68±0.21),t值分别为(-2.44±0.72)和(-1.66±0.55);左股骨颈BMD值分别为(0.74±0.22)和(0.86±0.08),t值分别为(-2.08±0.38)和(-1.42±0.46)(P<0.05)。对照组治疗前后腰椎BMD值分别为(0.67±0.14)和(0.69±0.09),t值分别为(-2.35±0.68)和(-1.86±0.36);左股骨颈BMD值分别为(0.72±0.16)和(0.75±0.24),t值分别为(-2.17±0.42)和(-1.71±0.32),对照组BMD值治疗前后有改善,但差异无统计学意义(P>0.05)。骨松宝联合钙尔奇D治疗比单用钙尔奇D治疗骨密度改善效果更为显著,差异具有统计学意义(P<0.05),无明显的不良反应。结论骨松宝联合钙尔奇D治疗对骨密度改善有显著疗效,并具有良好的耐受性和安全性。
Objective To investigate the therapeutic effect of Gusongbao combined with Caltrate D in the treatment of patients with osteopenia or osteoporosis. Methods Eighty patients with osteopenia or osteoporosis were randomly divided into two groups, the observation group （treated with Gusongbao combined with Caltrate D） and the control group （treated with Caltrate D）, with 40 cases in each group. The changes of bone mineral density （BMD） val- ue were observed after six months. Results Both BMD value and t value showed improvements in the two groups. The lumbar BMD value in the observation group before and after treatment was （0.60±0.12） and （0.68±0.21）, respec- tively, and lumbar t value was （-2.44±0.72） and （-1.66±0.55）, respectively; the left femoral neck BMD value was （0.74±0.22） and （0.86±0.08）, respectively, and t value was （-2.08±0.38） and （-1.42±0.46）, respectively （P〈0.05）. The lumbar BMD value in the control group before and alter treatment was （0.67±0.14） and （0.69±0.09）, respectively, and lumbar t value was （-2.35±0.68） and （-1.86a：0.36）, respectively; the left femoral neck BMD value was （0.72 ±0.16） and （0.75 ±0.24）, respectively, and t value was （-2.17±0.42） and （-1.71±0.32）, respectively （P〈0.05）. The improve- ment of bone mineral density in the observation group was greater than that in the control group （P〈0.05）, without se- vere adverse effect. Conclusion Gusongbao in combination with Caltrate D can significantly improve bone mineral density, with favorable tolerance and safety.
出处
《海南医学》
CAS
2013年第13期1898-1900,共3页
Hainan Medical Journal
基金
深圳市医学重点学科建设资助项目(编号:2005C10)
